{"id":237,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2001-03-07","marketCap":40706.05078125,"name":"Seagen Inc","phone":"14255274000.0","outstanding":187.6999969482422,"symbol":"SGEN","website":"https://www.seagen.com/","industry":"Biotechnology"},"price":216.5225,"year":2023,"month":10,"day":24,"weekday":"Tuesday","title":"Evaluation of Seagen Inc's Debt and Leverage Ratios and Their Impact on Stock Price Decline","date":"2023-10-24","url":"/posts/2023/10/24/SGEN","content":[{"section":"Introduction","text":"Seagen Inc, a biotechnology company specializing in the development of innovative cancer therapies, has recently experienced a decline in its stock price. This article explores the role of the company's debt and leverage ratios in this decline."},{"section":"Debt and Leverage Ratios","text":"Debt and leverage ratios are important financial metrics that provide insights into a company's financial health and its ability to meet its debt obligations. Seagen Inc's debt ratio indicates the proportion of the company's assets that are financed through debt. A high debt ratio implies that a significant portion of Seagen's assets are financed by debt rather than equity. The company's leverage ratio measures the extent to which it relies on borrowed funds to finance its operations."},{"section":"Impact on Stock Price","text":"Seagen Inc's high debt levels and leverage ratios can have a negative impact on its stock price. When a company has excessive debt, investors may become concerned about the company's ability to generate sufficient cash flows to service its debt obligations. This can erode investor confidence and lead to a decline in the stock price. Additionally, high debt levels increase the company's financial risk, as the costs of servicing the debt can become burdensome, especially during economic downturns or financial crises."},{"section":"Implications of High Debt Levels","text":"High debt levels can have several implications for Seagen Inc. Firstly, the company may face higher interest expenses, reducing its profitability and cash flows available for other purposes such as research and development or expansion. Secondly, high debt levels can limit the company's financial flexibility and ability to respond to changing market conditions. Seagen may be constrained in its ability to pursue strategic acquisitions or invest in new projects. Lastly, high levels of debt may also adversely impact the company's credit rating, increasing borrowing costs and making it more difficult to access capital in the future."},{"section":"Conclusion","text":"Seagen Inc's high debt and leverage ratios are contributing to the decline in its stock price. The company needs to address its high debt levels to restore investor confidence, improve its financial flexibility, and reduce its financial risk. By implementing strategies to reduce debt, such as deleveraging through asset sales or increasing profitability to generate more internal cash flows, Seagen can strengthen its financial position and potentially reverse the decline in its stock price."}],"tags":["OverBought","stock","Short","Biotechnology"],"news":[{"category":"company","date":1698067144,"headline":"Pfizer Stock: Interesting, If Discipline Returns","id":123339079,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg?io=getty-c-w1536","symbol":"SGEN","publisher":"SeekingAlpha","summary":"Pfizer's acquisition of Seagen is the latest in a series of M\u0026A deals fueled by pandemic-related profits. Read more to see a detailed analysis on PFE stock.","url":"https://seekingalpha.com/article/4642657-pfizer-stock-interesting-if-discipline-returns"},{"category":"company","date":1698054600,"headline":"First Week of January 2026 Options Trading For Seagen (SGEN)","id":123338388,"image":"","symbol":"SGEN","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3173410937"},{"category":"company","date":1698041351,"headline":"Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations","id":123333915,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413597282/image_1413597282.jpg?io=getty-c-w1536","symbol":"SGEN","publisher":"SeekingAlpha","summary":"Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Click here to read my analysis of DSKYF stock.","url":"https://seekingalpha.com/article/4642556-daiichi-sankyo-positive-long-term-outlook-with-high-market-expectations"},{"category":"company","date":1698034800,"headline":"BTIG Keeps Their Hold Rating on Seagen (SGEN)","id":123338392,"image":"","symbol":"SGEN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3173081420"},{"category":"company","date":1698033180,"headline":"Merck, Seagen, Astellas hail \"groundbreaking\" data for bladder cancer","id":123338394,"image":"","symbol":"SGEN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=wptgtjbmgz"},{"category":"company","date":1697985000,"headline":"Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer","id":123327467,"image":"https://media.zenfs.com/en/prnewswire.com/911bfc177560633ba4443e88d617e078","symbol":"SGEN","publisher":"Yahoo","summary":"Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, \"Astellas\") and Seagen Inc. (Nasdaq: SGEN) today announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) versus chemotherapy. The combination improved overall survival (OS) and progression-free survival (PFS) with statistically significant and clinically meaningful results in patients with previously untreated locally a","url":"https://finance.yahoo.com/news/groundbreaking-ev-302-trial-significantly-143000616.html"},{"category":"company","date":1697985000,"headline":"TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial","id":123329667,"image":"https://media.zenfs.com/en/business-wire.com/59c408021c8ee6771fef84ee5cfd63f3","symbol":"SGEN","publisher":"Yahoo","summary":"BOTHELL, Wash., \u0026 COPENHAGEN, Denmark, October 22, 2023--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced results today from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy (HR: 0.70, 95% CI: 0.54-0.89, p=0.","url":"https://finance.yahoo.com/news/tivdak-tisotumab-vedotin-tftv-significantly-143000684.html"},{"category":"company","date":1697946120,"headline":"Merck announces results from Phase 3 KEYNOTE-A39 trial","id":123338396,"image":"","symbol":"SGEN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3172617551"},{"category":"company","date":1697945040,"headline":"Seagen, Astellas announce results from Phase 3 EV-302 for PADCEV, Keytruda combo","id":123338398,"image":"","symbol":"SGEN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3172606625"},{"category":"company","date":1697944800,"headline":"Seagen, Genmab announce results from Phase 3 innovaTV 301 trial","id":123338399,"image":"","symbol":"SGEN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3172604409"},{"category":"company","date":1697826979,"headline":"A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)","id":123290753,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"SGEN","publisher":"Yahoo","summary":"Key Insights The projected fair value for Seagen is US$202 based on 2 Stage Free Cash Flow to Equity Seagen's US$215...","url":"https://finance.yahoo.com/news/look-fair-value-seagen-inc-183619781.html"},{"category":"company","date":1697785274,"headline":"Wall Street Breakfast: Graphite Curbs","id":123279481,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441154416/image_1441154416.jpg?io=getty-c-w1536","symbol":"SGEN","publisher":"SeekingAlpha","summary":"This article covers China curbing exports of EV battery material graphite, SolarEdge's slashed outlook, FCC looking to re-establish net neutrality, and CVS pulling phenylephrine medicines.","url":"https://seekingalpha.com/article/4642090-wall-street-breakfast-graphite-curbs"},{"category":"company","date":1697768580,"headline":"Notable Friday Option Activity: SGEN, W, GM","id":123300957,"image":"","symbol":"SGEN","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3170302241"},{"category":"company","date":1697763960,"headline":"TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal","id":123287292,"image":"","symbol":"SGEN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=yplu6biogr"},{"category":"company","date":1697715420,"headline":"EU clears Pfizer's USD43 billion takeover of biotech firm Seagen","id":123264397,"image":"","symbol":"SGEN","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=1ld6bu9mcx"},{"category":"company","date":1697709960,"headline":"Seagen ticks higher as EU approves $43B sale to Pfizer","id":123264399,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3168151587"},{"category":"company","date":1697709600,"headline":"Seagen ticks higher as Eupeon Union approves $43B sale to Pfizer","id":123264400,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3168143132"},{"category":"company","date":1697709180,"headline":"Pfizer receives unconditional approval for Seagen acquisition from EU","id":123264402,"image":"","symbol":"SGEN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3168134352"},{"category":"company","date":1697683887,"headline":"Truist Securities Reiterates Seagen (SGEN) Hold Recommendation","id":123249061,"image":"","symbol":"SGEN","publisher":"Fintel","summary":"","url":"https://fintel.io/news/truist-securities-reiterates-seagen-sgen-hold-recommendation-986"},{"category":"company","date":1697681040,"headline":"Pfizer (NYSE:PFE) Slides despite EU Nod to Seagen Acquisition","id":123264410,"image":"","symbol":"SGEN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3168493535"},{"category":"company","date":1697633343,"headline":"Incyte: One Of The Most Undervalued Pharmaceuticals","id":123232066,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413597282/image_1413597282.jpg?io=getty-c-w1536","symbol":"SGEN","publisher":"SeekingAlpha","summary":"Incyte stock declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Read more about INCY here.","url":"https://seekingalpha.com/article/4641563-incyte-one-of-the-most-undervalued-pharmaceuticals"},{"category":"company","date":1697618700,"headline":"Seagen abstract hits best case scenario, says RBC Capital","id":123234296,"image":"","symbol":"SGEN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3166230337"},{"category":"company","date":1697506500,"headline":"Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today","id":123215949,"image":"","symbol":"SGEN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3164808698"},{"category":"company","date":1697459460,"headline":"Pfizer (NYSE:PFE) Provides FTC with Documents for Seagen Acquisition","id":123190558,"image":"","symbol":"SGEN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3162841222"},{"category":"company","date":1697457600,"headline":"Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023","id":123187796,"image":"https://media.zenfs.com/en/business-wire.com/46b68a6028dd090d168a14b0efeb1767","symbol":"SGEN","publisher":"Yahoo","summary":"BOTHELL, Wash., October 16, 2023--Seagen Inc. (Nasdaq: SGEN) today announced the upcoming presentation of detailed results from two pivotal Phase 3 studies at the ESMO Congress 2023. Results from the EV-302 study of PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) in locally advanced or metastatic urothelial cancer (la/mUC) in the first-line setting will be presented during a Presidential Symposium at the Congress. Seagen will also present results from the innovaTV 301 study of TI","url":"https://finance.yahoo.com/news/seagen-highlight-overall-survival-data-120000512.html"},{"category":"company","date":1697454300,"headline":"Pfizer confronts ‘peak of anti-vaccination rhetoric’ as shares rebound","id":123217929,"image":"https://images.mktw.net/im-504042/social","symbol":"SGEN","publisher":"MarketWatch","summary":"Cost-saving program \"will touch all parts of the business\" but won't affect Seagen acquisition, Pfizer says.","url":"https://www.marketwatch.com/story/pfizer-confronts-peak-of-anti-vaccination-rhetoric-as-shares-rebound-54c5ef89"},{"category":"company","date":1697445720,"headline":"Pfizer likely turned over all documents to FTC for Seagen acquistion - report","id":123190573,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3162515157"},{"category":"company","date":1697445300,"headline":"Pfizer has turned over all documents to FTC for Seagen acquistion - report","id":123190576,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3162507051"},{"category":"company","date":1697445000,"headline":"Pfizer has turned over all the documents to FTC for Seagen acquistion - report","id":123190578,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3162499682"},{"category":"company","date":1697430600,"headline":"Pfizer upgraded to Buy from Hold at Jefferies","id":123190596,"image":"","symbol":"SGEN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3162269926"},{"category":"company","date":1697181420,"headline":"Hold Rating on Seagen: Balancing Potential Successes and Lingering Uncertainties in Urothelial Cancer Treatment Trials","id":123142341,"image":"","symbol":"SGEN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3158936653"},{"category":"company","date":1697162700,"headline":"Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event","id":123138531,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3159458379"},{"category":"company","date":1697112000,"headline":"Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023","id":123103717,"image":"https://media.zenfs.com/en/business-wire.com/c0e74eb682aba0ae9663404d1c859418","symbol":"SGEN","publisher":"Yahoo","summary":"BOTHELL, Wash., October 12, 2023--Seagen Inc. (Nasdaq: SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023.","url":"https://finance.yahoo.com/news/seagen-report-third-quarter-2023-120000579.html"},{"category":"company","date":1697016480,"headline":"Exxon’s $59.5 billion deal for Pioneer Natural Resources tops 2023 deals in moribund M\u0026A market","id":123106384,"image":"https://images.mktw.net/im-866370/social","symbol":"SGEN","publisher":"MarketWatch","summary":"Exxon's all-stock acquisition of Permian Basin oil and gas specialist beats out Pfizer's $44.6 billion acquisition of Seagen in a weak year for deals thus far.","url":"https://www.marketwatch.com/story/exxons-59-5-billion-deal-for-pioneer-natural-resources-tops-2023-deals-in-moribund-m-a-market-266932a3"},{"category":"company","date":1696995540,"headline":"Market Today: Pfizer's Acquisition of Seagen Under Review, NextEra Energy Rebounds, and Tempest ...","id":123090421,"image":"","symbol":"SGEN","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3156103400"},{"category":"company","date":1696994460,"headline":"Regulators looking at impact on innovation in review of Seagen/Pfizer - report","id":123091656,"image":"","symbol":"SGEN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3156078276"}]}